



Recent Authorization Changes for Priority Partners

Effective Date: Feb. 1 and April 20, 2026

Health Plans Affected: Priority Partners

Type of Change: Authorization Requirements Status

Explanation of Change:

Authorization status changes have been approved for Priority Partners as of Feb. 1 and April 20, 2026. These requirements affect members of all ages enrolled in Priority Partners.

Key: PA=Prior Authorization Required; NPA=No Prior Authorization Required

EPSDT Code Changes Effective April 20, 2026

- **L8615** – Headset/headpiece cochlear implant device replacement; **NPA**
- **L8625** – External recharging system for battery for use with cochlear implant or auditory osseointegrated device, replacement; **NPA**
- **L8693** – Auditory osseointegrated device, abutment, any length, replacement; **PA**
- **99002** – Handling/conveyance service for devices; **NPA**

MDH Lab Fee Schedule Update Effective Feb. 1, 2026

- **0530U** - Oncology (pan-solid tumor), ctDNA, utilizing plasma, next-generation sequencing (NGS) of 77 genes, 8 fusions, microsatellite instability, and tumor mutation burden, interpretative report for single-nucleotide variants, copy-number alterations, with therapy association; Liquid HALLMARK®, Lucence Health; **PA per EviCore**
- **0538U** - Oncology (solid tumor), next-generation targeted sequencing analysis, formalin-fixed paraffin-embedded (FFPE) tumor tissue, DNA analysis of 600 genes, interrogation for single-nucleotide variants, insertions/deletions, gene rearrangements, and copy number alterations, microsatellite instability, tumor mutation burden, reported as actionable variant; Predicine ATLAS™ Assay, Predicine Inc; **PA per EviCore**
- **0539U** - Oncology (solid tumor), cell-free circulating tumor DNA (ctDNA), 152 genes, next-generation sequencing, interrogation for single-nucleotide variants, insertions/deletions, gene rearrangements, copy number alterations, and microsatellite instability, using whole-blood samples, mutations with clinical actionability reported as actionable variant; PredicineCARE™ Assay, Predicine Inc; **PA per EviCore**
- **0540U** - Transplantation medicine, quantification of donor-derived cell-free DNA using next-generation sequencing analysis of plasma, reported as percentage of donor-derived cell-free DNA to determine probability of rejection; AlloSure®, CareDx® Lab; **PA per EviCore**
- **0543U** - Oncology (solid tumor), next-generation sequencing of DNA from formalin-fixed paraffin-embedded (FFPE) tissue of 517 genes, interrogation for single-nucleotide variants, multi-nucleotide variants, insertions and deletions from DNA, fusions in 24

genes and splice variants in 1 gene from RNA, and tumor mutation burden; TruSight™ Oncology Comprehensive, Illumina; **PA per EviCore**

- **0580U** - Borrelia burgdorferi, antibody detection of 24 recombinant protein groups, by immunoassay, IgG iDart™ Lyme IgG ImmunoBlot Kit, ID-FISH Technology; **NPA**
- **0583U** - Rare diseases (constitutional disease/hereditary disorders), rapid whole genome comparator DNA sequencing for single-nucleotide variants, insertions/deletions, copy number variations, blood, saliva, tissue sample, variants reported with proband results (List separately in addition to code for primary procedure); Rapid Genome Sequencing Family Member Comparator, Mayo Clinic; **PA per EviCore**
- **0585U** - Targeted genomic sequence analysis panel, solid organ neoplasm, circulating cell-free DNA (cfDNA) analysis from plasma of 521 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, and microsatellite instability, report shows identified mutations, including variants with clinical actionability; Labcorp® Plasma Complete™, Labcorp; **PA per EviCore**
- **0589U** - Perfluoroalkyl substances (PFAS) (eg, perfluorooctanoic acid, perfluorooctane sulfonic acid), 24 PFAS compounds by high-performance liquid chromatography with tandem mass spectrometry (LC-MS/MS), plasma or serum, quantitative PFAS (Forever Chemicals) Panel 2 – 24 PFAS, Quest Diagnostics®; **NPA**
- **0592U** - Oncology (hematolymphoid neoplasms), DNA, targeted genomic sequence of 417 genes, interrogation for gene fusions, translocations, rearrangements, utilizing formalin-fixed paraffin-embedded (FFPE) tumor tissue, results report clinically significant variant(s);
Aventa Lymphoma, Aventa Genomics; **PA per EviCore**
- **0598U** - Gastroenterology (irritable bowel syndrome), IgG antibodies to 18 food items by microarray-based immunoassay, whole blood or serum, report as elevated (positive) or normal (negative) antibody levels; Foods® IBS, Ethos Laboratories, Biomerica; **NPA**

Prior Authorization Process for Priority Partners: Please use our secure online portal, [Availity](#), to submit electronic prior authorization requests.